[Effects of cimetidine, antacids and free diet on the pH of gastric content, in patients with peptic ulcer].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J A Salgado.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Ninety four adult outpatients entered a randomized trial in which 30 patients were treated openly with antacid hourly and 64 patients with a double-blind regimen of either cimetidine (1 g/day) or placebo. After 4 weeks, 66.3% of the antacid-treated patients, 56.2% of the cimetidine-treated patients and 9.4% of the placebo patients showed ulcer healing. The difference between cimetidine and antacid was not statistically significant. The low percentage in the placebo group as compared to other trials may be attributed to the avoidance of supplementary antacid in this group and or to the criterion of staging the lesions both for entry into study and for evaluating the results.
The effect of cimetidine, a histamine H2-receptor antagonist, on basal and beta-zole-stimulated gastric acid secretion was studied in 28 patients with peptic ulcer. The results demonstrate that cimetidine (300 mg IM), is a potent inhibitor of both basal and betazole-stimulated gastric acid secretion.